Lindbrook Capital, LLC Allovir, Inc. Transaction History

Lindbrook Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	BUY	$3.17 - $5.82 $852 - $1,565	269 Added 72.7%	639 $2,000
Q1 2023 Apr 26, 2023	BUY	$3.94 - $7.05 $1,457 - $2,608	370 New	370 $1,000
Q3 2022 Nov 10, 2022	BUY	$4.13 - $8.79 $1,598 - $3,401	387 New	387 $3,000
Q2 2022 Aug 01, 2022	SELL	$3.26 - $7.06 $873 - $1,892	-268 Closed	0 $0
Q1 2022 Apr 21, 2022	BUY	$6.75 - $13.52 $1,809 - $3,623	268 New	268 $2,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $51.2M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.